The pharmaceutical company has approved capital investments of more than ₹4,000 crore over the past two years to expand its manufacturing capabilities across multiple therapeutic areas. According to the company's annual report, these investments focus on respiratory active pharmaceutical ingredient (API) capacity, oncology ingredient manufacturing, inhalation capabilities and global production infrastructure. Managing Director and Global Chief Executive Officer Achin Gupta stated that the company has commissioned its greenfield respiratory API facility at Kurkumbh in Maharashtra and is continuing expansion across oncology APIs, inhalation products and key dosage forms.
The expansion programme includes scaling up the oncology API block at Bommasandra in Karnataka and augmenting manufacturing capacity across facilities in Goa, Sikkim and Patalganga. In respiratory therapies, Cipla has added new respule production lines in Goa and China, while additional lines are being commissioned to support growing demand. The company has also expanded its inhalation manufacturing network in the US, with its metered-dose inhaler (MDI) facility in Fall River, Massachusetts, securing approvals for gProventil and gVentolin, while its dry powder inhaler (DPI) facility in Long Island supports the commercialisation of gAdvair and other products. Cipla currently operates over 40 state-of-the-art manufacturing facilities globally, including facilities in the USA, China, and South Africa, alongside its India operations.
Cipla's flagship respiratory brand Foracort crossed the ₹1,000-crore revenue milestone during FY26, as reported by the company. The company derives a significant share of its business from respiratory therapies, making this achievement particularly significant for its core operations. During FY26, Cipla filed 10 applications with the US Food and Drug Administration, spanning respiratory inhalation products, peptide-based injectables and complex generics, as it continues to build a pipeline of differentiated products for regulated markets. The company maintains a diversified portfolio of more than 1,500 products in over 50 dosage forms and 65 therapeutic categories, positioning it as a market leader in respiratory and urology therapies.
The investments come at a time when pharmaceutical companies are increasingly focusing on complex and specialty therapies such as inhalation products, oncology medicines, biosimilars and peptide-based products, which typically offer higher entry barriers and lower competition than conventional generics. According to the company, the manufacturing expansion is aimed at strengthening supply-chain integration, scaling capabilities for regulated markets and supporting future growth across India, North America, Africa and emerging markets. Cipla also highlighted ongoing investments in next-generation modalities, including biosimilars and oligonucleotides, alongside partnerships in metabolic and respiratory care. The company's geographic revenue mix shows India contributing slightly less than 50% of revenues, while North America provides around 22% as of September 2023.
